{
    "clinical_study": {
        "@rank": "67165", 
        "arm_group": {
            "arm_group_label": "Screening (HSIL detection)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture 2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 6, 12, 18, and 24 months."
        }, 
        "brief_summary": {
            "textblock": "This clinical trial studies anal human papillomavirus (HPV) tests in screening for cell\n      changes in the anus in patients with human immunodeficiency virus (HIV). Screening tests may\n      help doctors find cancer cells early and plan better treatment for anal cancer. Completing\n      multiple screening tests may help find the best method for detecting cell changes in the\n      anus."
        }, 
        "brief_title": "Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Anal Cancer", 
            "HIV Infection", 
            "Human Papilloma Virus Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Anus Neoplasms", 
                "Papilloma", 
                "Virus Diseases", 
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the sensitivity and specificity of HPV testing using different methods of\n      detection, including HPV Hybrid Capture 2 (HC2), HPV messenger ribonucleic acid (mRNA)\n      assays (APTIMA) and OncoHealth HPV E6/E7 oncoprotein assay and whether they improve the\n      screening performance of routine anal cytology for the detection of anal high-grade squamous\n      intraepithelial lesions (HSIL) when measured against the gold standard, biopsy-proven HSIL.\n\n      II. To determine the prevalence and risk factors for prevalent HSIL in HIV-infected women.\n\n      III. To determine incidence and risk factors associated with anal HSIL and HPV over 2 years\n      among HIV infected women undergoing semi-annual anal evaluations.\n\n      SECONDARY OBJECTIVES:\n\n      I. To evaluate the acceptability of anal cancer screening among HIV-infected women.\n\n      II. To collect data on quality of life and health care costs (including non-direct health\n      care costs and time costs) for an economic evaluation of the cost-effectiveness of anal\n      cancer screening strategies in HIV-positive women.\n\n      OUTLINE:\n\n      Patients undergo screening for the detection of HSIL using anal cytology, HPV hybrid capture\n      2, HPV mRNA assays, and OncoHealth HPVE6/E7 oncoprotein at baseline, at 12 and 24 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV positive; HIV-1 infection, as documented by any federally approved, licensed HIV\n             rapid test performed in conjunction with screening (or enzyme-linked immunosorbent\n             assay [ELISA], test kit, and confirmed by Western blot or other approved test);\n             alternatively, this documentation may include a record that another physician has\n             documented that the participant has HIV infection based on prior ELISA and Western\n             blot, or other approved diagnostic tests\n\n          -  Karnofsky performance status > 70%\n\n          -  Absolute neutrophil count >= 750 cells/mm^3 within 120 days of study entry\n\n          -  Platelet count >= 75,000 cells/mm^3 within 120 days of study entry\n\n        Exclusion Criteria:\n\n          -  Current or history of anal or perianal carcinoma\n\n          -  History of anal HSIL cytology or histology\n\n          -  Known permanent or irreversible bleeding disorder, or any illness that, in the\n             opinion of the clinical investigator, would contraindicate any biopsy of the anal\n             canal\n\n          -  For women able to conceive, evidence of pregnancy by a positive urinary pregnancy\n             test; pregnant women are excluded from enrollment in this study\n\n          -  Serious medical or psychiatric illness that in the opinion of the site Investigator\n             will interfere with the ability of the subject to give informed consent or adhere to\n             the protocol\n\n          -  Ongoing use of anticoagulant therapy other than aspirin, clopidogrel or non-steroidal\n             anti-inflammatory drugs (NSAIDS)\n\n          -  Inability to provide informed consent\n\n          -  Treatment of anal and/or perianal HPV associated disease (i.e., condyloma or\n             low-grade anal intraepithelial neoplasia [AIN]) within 4 months of study entry"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01946139", 
            "org_study_id": "AMC-084", 
            "secondary_id": [
                "NCI-2013-01637", 
                "AMC-084", 
                "AMC-084", 
                "R01CA163103", 
                "U01CA121947"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Screening (HSIL detection)", 
                "description": "Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays", 
                "intervention_name": "comparison of screening methods", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Screening (HSIL detection)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Screening (HSIL detection)", 
                "description": "Ancillary studies", 
                "intervention_name": "questionnaire administration", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Screening (HSIL detection)", 
                "description": "Ancillary studies", 
                "intervention_name": "quality-of-life assessment", 
                "intervention_type": "Procedure", 
                "other_name": "quality of life assessment"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mmgonzalez@mednet.ucla.edu", 
                    "last_name": "Marisol Gonzalez", 
                    "phone": "301-557-3729"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095-1793"
                    }, 
                    "name": "UCLA Clinical AIDS Research and Education (CARE) Center"
                }, 
                "investigator": {
                    "last_name": "Ronald Mitsuyasu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "John H. Stroger Hospital of Cook County"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Elizabeth Stier, MD", 
                    "phone": "617-414-5175"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02118"
                    }, 
                    "name": "Boston University Cancer Research Center"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Stier, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Marisol Rivera", 
                    "phone": "718-405-8397"
                }, 
                "contact_backup": {
                    "last_name": "Mary Sanvardeker", 
                    "phone": "718-405-8394"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10461"
                    }, 
                    "name": "Montefiore Medical Center"
                }, 
                "investigator": {
                    "last_name": "Mark Einstein, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "orissca@upmc.edu", 
                    "last_name": "Carol Oriss", 
                    "phone": "412-383-1434"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15261"
                    }, 
                    "name": "University of Pittsburgh School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Ross Cranston, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "echiao@bcm.edu", 
                    "last_name": "Elizabeth Y. Chiao", 
                    "phone": "713-794-8666"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }, 
                "investigator": {
                    "last_name": "Elizabeth Y. Chiao", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Screening HIV-Infected Women for Anal Cancer Precursors", 
        "overall_official": {
            "affiliation": "AIDS Associated Malignancies Clinical Trials Consortium", 
            "last_name": "Elizabeth Chiao", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Federal Government", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The binomial proportion and its 95% confidence interval will be used. Among patients who are high resolution anoscopy (HRA) positive for HSIL, McNemar's test will be used to compare routine anal cytology with each of the other methods of detection to determine if sensitivity in the diagnosis of HSIL is improved with the other methods. Positive and negative predictive values will be estimated for each method of detection.", 
                "measure": "Sensitivity of each of the methods of HSIL detection (anal cytology APTIMA, HC2 and OncoHealth HPVE6/E7 oncoprotein)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "Among patients who are HRA negative for HSIL, McNemar's test will be used to compare routine anal cytology with each of the other methods of HPV detection to improve specificity. Positive and negative predictive values will be estimated for each method of detection.", 
                "measure": "Specificity of each other methods of HSIL detection (anal cytology, APTIMA, HC2, and OncoHealth HPVE6/7)", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The prevalence of HSIL will be estimated as the proportion of women who are HRA positive for HSIL at entry and its 95% confidence interval. Logistic regression analysis will be used to evaluate the association of potential risk factors with diagnosis of HSIL.", 
                "measure": "Prevalence of HSIL", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The Poisson rate and its 95% confidence interval will be estimated from the number of HSIL cases detected divided  by the cumulative years of follow-up across these cases. Behavioral risk factors will be assessed by research staff administered surveys at each study visit. Logistic regression will be used to evaluate potential risk factors for incidence of HSIL.", 
                "measure": "Incidence of HSIL among women who were HRA negative for HSIL at study entry", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }, 
            {
                "description": "The Poisson rate and its 95% confidence interval will be estimated from the number of anal HPV cases detected divided by the cumulative years of follow-up across these cases. Logistic regression will be used to evaluate potential risk factors for incidence of anal HPV.", 
                "measure": "Incidence of anal HPV among women who were negative for anal HPV at study entry", 
                "safety_issue": "No", 
                "time_frame": "Up to 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01946139"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Descriptive statistics will be used to characterize subjects' acceptability of undergoing anal screening with cytology/HPV and HRA throughout the study to evaluate changes in perceptions. Generalized estimating equations (GEE) will be used to assess acceptability over time adjusting for intrapatient variability. Acceptability will be correlated with clinical and behavioral risk factors, e.g., history of sexual assault, depression, anxiety, medication compliance, sexual behaviors using GEE methods.", 
            "measure": "Acceptability of anal cancer screening among HIV-infected women based on survey responses regarding patient satisfaction and phone call surveys", 
            "safety_issue": "No", 
            "time_frame": "Up to 2 years"
        }, 
        "source": "AIDS Malignancy Clinical Trials Consortium", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "AIDS Malignancy Clinical Trials Consortium", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}